# A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)

> **NCT04194203** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 305 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Placebo
- **DRUG:** Bevacizumab
- **DRUG:** Paclitaxel
- **DRUG:** Pemetrexed
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT04194203
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-09
- **Primary completion:** 2023-02-02
- **Final completion:** 2024-06-27
- **Target enrollment:** 305 (ACTUAL)
- **Last updated:** 2024-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04194203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04194203, "A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04194203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*